04361nam 2200721Ia 450 991082115270332120240508231612.01-118-03518-61-282-70769-897866127076980-470-62652-60-470-62651-8(CKB)2670000000035070(EBL)564932(OCoLC)662452551(SSID)ssj0000416714(PQKBManifestationID)11296960(PQKBTitleCode)TC0000416714(PQKBWorkID)10422988(PQKB)11572832(MiAaPQ)EBC564932(Au-PeEL)EBL564932(CaPaEBR)ebr10411514(CaONFJC)MIL270769(PPN)19807851X(EXLCZ)99267000000003507020091223d2010 uy 0engur|n|---|||||txtccrEmerging cancer therapy microbial approaches and biotechnological tools /edited by Arsenio M. Fialho, Ananda M. Chakrabarty1st ed.Hoboken, N.J. Wileyc20101 online resource (448 p.)Wiley series in biotechnology and bioengineeringDescription based upon print version of record.0-470-44467-3 Includes bibliographical references and index.EMERGING CANCER THERAPY; CONTENTS; PREFACE; CONTRIBUTORS; PART I: LIVE/ATTENUATED BACTERIA AND VIRUSES AS ANTICANCER AGENTS; 1: SALMONELLA TYPHIMURIUM MUTANTS SELECTED TO GROW ONLY IN TUMORS TO ERADICATE THEM IN NUDE MOUSE MODELS; 2: THE USE OF LIVING LISTERIA MONOCYTOGENES AS AN ACTIVE IMMUNOTHERAPY FOR THE TREATMENT OF CANCER; 3: BACILLUS CALMETTE-GUERIN( BCG ) FOR UROTHELIAL CARCINOMA OF THE BLADDER; 4: LIVE CLOSTRIDIA : A POWERFUL TOOL IN TUMOR BIOTHERAPY; 5: BIFIDOBACTERIUM AS A DELIVERY SYSTEM OF FUNCTIONAL GENES FOR CANCER GENE THERAPY6: REPLICATION-SELECTIVE VIRUSES FOR THE TREATMENT OF CANCER7: ENGINEERING HERPES SIMPLEX VIRUS FOR CANCER ONCOLYTIC VIROTHERAPY; PART II: BACTERIAL PRODUCTS AS ANTICANCER AGENTS; 8: PROMISCUOUS ANTICANCER DRUGS FROM PATHOGENIC BACTERIA: RATIONAL VERSUS INTELLIGENT DRUG DESIGN; 9: ARGININE DEIMINASE AND CANCER THERAPY; 10: CYTOSINE DEAMINASE/5-FLUOROCYTOSINE MOLECULAR CANCER CHEMOTHERAPY; 11: BACTERIAL PROTEINS AGAINST METASTASIS; 12: PSEUDOMONAS EXOTOXIN A-BASED IMMUNOTOXINS FOR TARGETED CANCER THERAPY; 13: DENILEUKIN DIFTITOX IN NOVEL CANCER THERAPY14: THE APPLICATION OF CATIONIC ANTIMICROBIAL PEPTIDES IN CANCER TREATMENT: LABORATORY INVESTIGATIONS AND CLINICAL POTENTIAL15: PRODIGININES AND THEIR POTENTIAL UTILITY AS PROAPOPTOTIC ANTICANCER AGENTS; 16: FARNESYLTRANSFERASE INHIBITORS OF MICROBIAL ORIGINS IN CANCER THERAPY; 17: THE USE OF RNA AND CpG DNN AS NUCLEIC ACID-BASEDTHERAPEUTICS; PART III: PATENTS ON BACTERIA/BACTERIAL PRODUCTS AS ANTICANCER AGENTS; 18: THE ROLE AND IMPORTANCE OF INTELLECTUAL PROPERTY GENERATION AND PROTECTION IN DRUG DEVELOPMENT; INDEXExplores current and emerging applications of microbes as cancer-fighting agents Today, treatment options for cancer patients typically include surgery, radiation therapy, immunotherapy, and chemotherapy. While these therapies have saved lives and reduced pain and suffering, cancer still takes millions of lives every year around the world. In recent years, researchers have been working on a new strategy: developing microbes and microbial products that specifically attack cancer cells. This book breaks new ground in emerging cancer treatment modalities by presenting recent advances iWiley series in biotechnology and bioengineering.CancerTreatmentVirusesTherapeutic useBacteriaTherapeutic useMicrobial biotechnologyCancerTreatment.VirusesTherapeutic use.BacteriaTherapeutic use.Microbial biotechnology.616.99/406Fialho Arsenio1720745Chakrabarty Ananda M.1938-1720746MiAaPQMiAaPQMiAaPQBOOK9910821152703321Emerging cancer therapy4119738UNINA